• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness.一项旨在降低严重精神疾病患者心血管风险的干预措施的实用临床试验设计。
Contemp Clin Trials. 2020 Apr;91:105964. doi: 10.1016/j.cct.2020.105964. Epub 2020 Feb 20.
2
Effect of Clinical Decision Support on Cardiovascular Risk Among Adults With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia: A Cluster Randomized Clinical Trial.临床决策支持对双相情感障碍、分裂情感性障碍或精神分裂症成人心血管风险的影响:一项集群随机临床试验。
JAMA Netw Open. 2022 Mar 1;5(3):e220202. doi: 10.1001/jamanetworkopen.2022.0202.
3
Implementing a prediabetes clinical decision support system in a large primary care system: Design, methods, and pre-implementation results.在大型初级保健系统中实施糖尿病前期临床决策支持系统:设计、方法和实施前结果。
Contemp Clin Trials. 2022 Mar;114:106686. doi: 10.1016/j.cct.2022.106686. Epub 2022 Jan 25.
4
Differential Effects of an Intervention to Reduce Cardiovascular Risk for Patients With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia: A Randomized Clinical Trial.干预对双相情感障碍、分裂情感性障碍或精神分裂症患者心血管风险的差异影响:一项随机临床试验。
J Clin Psychiatry. 2023 Jul 5;84(4):22m14710. doi: 10.4088/JCP.22m14710.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Clinical decision support directed to primary care patients and providers reduces cardiovascular risk: a randomized trial.临床决策支持针对初级保健患者和提供者可降低心血管风险:一项随机试验。
J Am Med Inform Assoc. 2018 Sep 1;25(9):1137-1146. doi: 10.1093/jamia/ocy085.
7
Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.伴有或不伴有精神分裂症、分裂情感性障碍或双相情感障碍的患者的心血管风险。
J Am Heart Assoc. 2022 Mar 15;11(6):e021444. doi: 10.1161/JAHA.121.021444. Epub 2022 Mar 9.
8
Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service.重度精神疾病戒烟干预试验(SCIMITAR):一项定制戒烟服务的临床有效性和成本效益的试点随机对照试验。
Health Technol Assess. 2015 Mar;19(25):1-148, v-vi. doi: 10.3310/hta19250.
9
A bespoke smoking cessation service compared with treatment as usual for people with severe mental ill health: the SCIMITAR+ RCT.针对严重精神健康问题患者的定制化戒烟服务与常规治疗相比:SCIMITAR+RCT。
Health Technol Assess. 2019 Sep;23(50):1-116. doi: 10.3310/hta23500.
10
Cost-effectiveness of a lifestyle intervention for people with a serious mental illness (SMILE): design of a pragmatic cluster-randomised controlled trial.生活方式干预对严重精神疾病患者(SMILE)的成本效益:一项实用的集群随机对照试验设计。
BMC Psychiatry. 2019 May 16;19(1):151. doi: 10.1186/s12888-019-2132-5.

引用本文的文献

1
Strategies to improve the implementation of preventive care in primary care: a systematic review and meta-analysis.提高初级保健中预防保健实施的策略:系统评价和荟萃分析。
BMC Med. 2024 Sep 27;22(1):412. doi: 10.1186/s12916-024-03588-5.
2
30-year Cardiovascular Disease Risk for Young Adults with Serious Mental Illness.年轻人严重精神疾病 30 年心血管疾病风险。
Gen Hosp Psychiatry. 2023 Nov-Dec;85:139-147. doi: 10.1016/j.genhosppsych.2023.10.015. Epub 2023 Oct 21.
3
Barriers and facilitators to the participation and engagement of primary care in shared-care arrangements with community mental health services for preventive care of people with serious mental illness: a scoping review.初级保健参与和参与社区心理健康服务共享护理安排以预防严重精神疾病患者的障碍和促进因素:范围审查。
BMC Health Serv Res. 2023 Sep 11;23(1):977. doi: 10.1186/s12913-023-09918-2.
4
Differential Effects of an Intervention to Reduce Cardiovascular Risk for Patients With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia: A Randomized Clinical Trial.干预对双相情感障碍、分裂情感性障碍或精神分裂症患者心血管风险的差异影响:一项随机临床试验。
J Clin Psychiatry. 2023 Jul 5;84(4):22m14710. doi: 10.4088/JCP.22m14710.
5
Depression and cardiovascular risk in primary care patients.基层医疗患者中的抑郁与心血管风险。
J Psychosom Res. 2022 Jul;158:110920. doi: 10.1016/j.jpsychores.2022.110920. Epub 2022 Apr 19.
6
Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder.伴有或不伴有精神分裂症、分裂情感性障碍或双相情感障碍的患者的心血管风险。
J Am Heart Assoc. 2022 Mar 15;11(6):e021444. doi: 10.1161/JAHA.121.021444. Epub 2022 Mar 9.
7
Effect of Clinical Decision Support on Cardiovascular Risk Among Adults With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia: A Cluster Randomized Clinical Trial.临床决策支持对双相情感障碍、分裂情感性障碍或精神分裂症成人心血管风险的影响:一项集群随机临床试验。
JAMA Netw Open. 2022 Mar 1;5(3):e220202. doi: 10.1001/jamanetworkopen.2022.0202.
8
Cardiovascular disease in patients with severe mental illness.严重精神疾病患者的心血管疾病。
Nat Rev Cardiol. 2021 Feb;18(2):136-145. doi: 10.1038/s41569-020-00463-7. Epub 2020 Oct 30.

本文引用的文献

1
Clinical decision support directed to primary care patients and providers reduces cardiovascular risk: a randomized trial.临床决策支持针对初级保健患者和提供者可降低心血管风险:一项随机试验。
J Am Med Inform Assoc. 2018 Sep 1;25(9):1137-1146. doi: 10.1093/jamia/ocy085.
2
Clinical Decision Support for Recognition and Management of Hypertension: A Randomized Trial.临床决策支持在识别和管理高血压中的应用:一项随机试验。
Pediatrics. 2018 Feb;141(2). doi: 10.1542/peds.2017-2954.
3
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.抗精神病药物所致体重增加:管理策略及其对治疗依从性的影响
Neuropsychiatr Dis Treat. 2017 Aug 22;13:2231-2241. doi: 10.2147/NDT.S113099. eCollection 2017.
4
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会心血管风险评估指南:美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005. Epub 2013 Nov 12.
5
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会心血管风险评估指南:美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98. Epub 2013 Nov 12.
6
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.UKPDS 结局模型 2:使用来自英国前瞻性糖尿病研究 30 年的数据模拟 2 型糖尿病患者终生健康结局的模型新版本:UKPDS 82。
Diabetologia. 2013 Sep;56(9):1925-33. doi: 10.1007/s00125-013-2940-y. Epub 2013 Jun 22.
7
Cardiovascular morbidity and mortality in bipolar disorder.双相情感障碍中的心血管疾病发病率和死亡率。
Ann Clin Psychiatry. 2011 Feb;23(1):40-7.
8
Impact of electronic health record clinical decision support on diabetes care: a randomized trial.电子健康记录临床决策支持对糖尿病护理的影响:一项随机试验。
Ann Fam Med. 2011 Jan-Feb;9(1):12-21. doi: 10.1370/afm.1196.
9
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.针对患有精神分裂症且存在抗精神病药物所致体重或代谢问题的患者进行抗精神病药物转换。
Cochrane Database Syst Rev. 2010 Dec 8;2010(12):CD006629. doi: 10.1002/14651858.CD006629.pub2.
10
Minnesota 10 by 10. Reducing morbidity and mortality in people with serious mental illnesses.明尼苏达10乘10计划。降低严重精神疾病患者的发病率和死亡率。
Minn Med. 2010 Jun;93(6):38-41.

一项旨在降低严重精神疾病患者心血管风险的干预措施的实用临床试验设计。

Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness.

机构信息

HealthPartners Institute, Minneapolis, MN, United States of America.

HealthPartners Institute, Minneapolis, MN, United States of America.

出版信息

Contemp Clin Trials. 2020 Apr;91:105964. doi: 10.1016/j.cct.2020.105964. Epub 2020 Feb 20.

DOI:10.1016/j.cct.2020.105964
PMID:32087336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7263956/
Abstract

BACKGROUND

Cardiovascular (CV) disease is the leading cause of death for people with serious mental illness (SMI), but clinicians are often slow to address this risk.

METHODS/DESIGN: 78 Midwestern primary care clinics were randomized to receive or not receive access to a clinical decision support (CDS) tool. Between March 2016 and September 2018, primary care clinicians (PCPs) received CDS alerts during visits with adult patients with SMI who met minimal inclusion criteria and had at least one CV risk factor not at goal. The PCP CDS included a summary of six modifiable CV risk factors and patient-specific treatment recommendations. Psychiatrists received CDS alerts during their next visit with an eligible patient with SMI that alerted them to an elevated body mass index or recent weight gain and the presence of an obesogenic SMI medication. Study outcomes include total modifiable CV risk, six modifiable CV risk factors, and use of obesogenic SMI medications.

DISCUSSION

This cluster-randomized pragmatic trial allowed PCPs and psychiatrists the opportunity to improve CV risk in a timely manner for patients with SMI. Effectiveness will be assessed using an intent-to-treat analysis, and outcomes will be assessed largely through electronic health record data harvested by the CDS tool itself. In total, 10,347 patients with SMI had an index primary care visit in a randomized clinic, and 8937 patients had at least one follow-up visit. Analyses are ongoing, and trial results are expected in mid-2020.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT02451670.

摘要

背景

心血管疾病是严重精神疾病(SMI)患者的主要死亡原因,但临床医生往往迟迟未能解决这一风险。

方法/设计:78 家中西部初级保健诊所被随机分配接受或不接受临床决策支持(CDS)工具。在 2016 年 3 月至 2018 年 9 月期间,初级保健医生(PCP)在接受符合最低纳入标准且至少有一种未达标的心血管危险因素的 SMI 成年患者就诊时收到 CDS 警报。PCP 的 CDS 包括六个可修改的心血管危险因素摘要和患者特定的治疗建议。在符合条件的 SMI 患者下次就诊时,精神科医生会收到 CDS 警报,提醒他们注意体重指数升高或近期体重增加,以及存在肥胖型 SMI 药物。研究结果包括总可修改的心血管风险、六个可修改的心血管危险因素和肥胖型 SMI 药物的使用。

讨论

这项聚类随机实用试验为 PCP 和精神科医生提供了及时改善 SMI 患者心血管风险的机会。将使用意向治疗分析评估有效性,并且主要通过 CDS 工具本身收集的电子健康记录数据评估结果。共有 10347 名 SMI 患者在随机诊所进行了索引初级保健就诊,8937 名患者至少进行了一次随访就诊。分析正在进行中,预计 2020 年年中会得出试验结果。

试验注册

ClinicalTrials.gov 标识符:NCT02451670。